In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scion Pharmaceuticals Inc.

www.scionpharma.com

Latest From Scion Pharmaceuticals Inc.

Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
BioPharmaceutical Business Strategies

Enabling a Comeback in Ion Channel Drug Discovery

Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx looks at Sophion Bioscience, Nanion Technologies, and Xention Discovery, three emerging European firms whose platforms may help return ion channels to the forefront of biotech and pharmaceutical companies' discovery targets.
BioPharmaceutical Europe

The Re-Emergence of Ion Channel Drug Discovery

Historically ion channels have been among the most attractive targets for therapeutic intervention. But discovery of new ion channel drugs has come to a halt because ion channels are difficult to assay, require specialized tools and skills to study adequately, and have historically been impossible to study directly in high-throughput mode-the preferred style of the last decade. Now, a variety of automated assay technologies are coming on the market that should increase throughput, and some drug discovery companies have developed proprietary high-throughput methods for in-house use. With industry now interested more than ever in applying higher-throughput technologies to precedented targets, in a sense, ion channel discovery may become a beneficiary of the failures of genomics, combinatorial chemistry, and high-throughput screening.
BioPharmaceutical Platform Technologies

Start-Up Previews (10/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Glycomics, features profiles of Ancora Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Optimer Pharmaceuticals Inc. and Thios Pharmaceuticals Inc. Plus these selected Start-Ups across Health Care: AngioLink Corp., PhageTech Inc., Scion Pharmaceuticals Inc. and Tensor Biosciences.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Scion Pharmaceuticals Inc.
  • Senior Management
  • Barry A Berkowitz, PhD, Pres. & CEO
    Jeffrey S Williams, VP, Corp. Dev.
    Aninda Katragadda, VP, Fin.
  • Contact Info
  • Scion Pharmaceuticals Inc.
    Phone: (781) 391-1900
    200 Boston Ave.
    Ste. 3600
    Medford, MA 02155
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register